Piper Sandler Reiterates Overweight on Cue Biopharma, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Cue Biopharma (NASDAQ:CUE) and maintained an $8 price target.
April 03, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Cue Biopharma and maintained an $8 price target.
The reiteration of an Overweight rating and maintenance of an $8 price target by a reputable analyst like Edward Tenthoff suggests a positive outlook for Cue Biopharma. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100